A Phase IV, prospective, open-label, uncontrolled, single-centre cohort trial to be conducted in Norway to assess the responsiveness of subjects with phenylketonuria (PKU) to treatment with Kuvan® 20 mg/kg/day for 7 days.
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Sponsors Merck Serono
- 05 Oct 2017 New trial record